Skip to main content

How can we help you?

  • 28-01-2013

NautaDutilh advised the shareholders of Uteron Pharma SA on the sale of 100% of Uteron's issued securities to (a subsidiary of) Watson Pharmaceuticals, Inc., listed on the NYSE, for an upfront purchase price of USD 150 mio in cash and up to USD 155 mio in potential future milestone payments. The deal closed on 23 January 2013.

Uteron Pharma, a spin-off of the University of Liège, is a development-based company dedicated to female healthcare. Uteron has a diversified portfolio of innovative products in different stages of development. Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.

The team of NautaDutilh was led by Elke Janssens and consisted of Virginie Ciers, Christel Brion, Pierre-Yves Thoumsin, Karel Nijs, Hannes Abraham, Olga Matiychuk, Karolien Boghe, Julie Salteur, Harry Eliaerts, Olivia Ledoux, Lorraine Vercauteren-Drubbel, Philippine De Wolf, David Mussche, Pascal Faes, Elodie Wagnon, Thomas Dreier, Jens Mosselmans, Julien Hick, Geneviève Borremans, Thomas Verstraeten, Olivier Van Raemdonck and Philippe Péters. NautaDutilh Netherlands (Jaap Stoop) was also involved for some Dutch aspects.

Source: NautaDutilh

This publication is also available in Dutch.

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.